SARGRAMOSTIM for Alveolar proteinosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 44 adverse event reports in the FDA FAERS database where SARGRAMOSTIM was used for Alveolar proteinosis.
Most Reported Side Effects for SARGRAMOSTIM
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 98 | 16.5% | 12 | 10 |
| Pyrexia | 76 | 12.8% | 3 | 23 |
| Pain | 56 | 9.4% | 2 | 1 |
| Hospitalisation | 31 | 5.2% | 0 | 24 |
| Death | 30 | 5.1% | 29 | 0 |
| Hypotension | 25 | 4.2% | 3 | 18 |
| Device related infection | 23 | 3.9% | 1 | 1 |
| Cough | 20 | 3.4% | 1 | 4 |
| Febrile neutropenia | 20 | 3.4% | 1 | 5 |
| Disease progression | 18 | 3.0% | 9 | 1 |
| Device related bacteraemia | 17 | 2.9% | 0 | 0 |
| Fatigue | 16 | 2.7% | 1 | 8 |
| Hypersensitivity | 16 | 2.7% | 0 | 4 |
| Nausea | 16 | 2.7% | 3 | 2 |
| Injection site erythema | 14 | 2.4% | 0 | 0 |
Other Indications for SARGRAMOSTIM
Neuroblastoma (88)
Product used for unknown indication (48)
Pancreatic carcinoma (40)
Pancreatic carcinoma metastatic (39)
Neutropenia (35)
Adrenal gland cancer (26)
Malignant melanoma (24)
Prostate cancer (17)
Neoplasm malignant (12)
Bladder cancer (7)